Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance

AbbVie IncTrade
ABRDN Physical Gold Shares ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs ABRDN Physical Gold Shares ETF — how do they compare? AbbVie Inc trades at $248.98 (market cap $441.94B), while ABRDN Physical Gold Shares ETF trades at $42.06. The key difference: AbbVie Inc pays a 2.77% dividend while ABRDN Physical Gold Shares ETF pays none, and AbbVie Inc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.

ABBVSGOL
Market Cap
$441.94B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$263.58$51.41
52-Week Low
$197.38$31.61
Enterprise Value
$506.19B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

ABRDN Physical Gold Shares ETF

SGOL, a US-listed gold ETF, trades at $41.35, up 2.22% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights gold's rebound potential, driven by central bank buying and dovish Fed expectations. The stock shows strong support at $41 and resistance at $42, with institutional sentiment leaning positive amid macroeconomic support for precious metals.

Outlook remains cautiously optimistic as gold benefits from lower real yields and geopolitical factors, though overbought conditions near-term pose a risk. Investment appeal hinges on sustained macroeconomic trends, while volatility from dollar movements and profit-taking presents challenges for short-term holders.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About ABRDN Physical Gold Shares ETF

SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.

Read more on SGOL